<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132466</url>
  </required_header>
  <id_info>
    <org_study_id>3333934_C</org_study_id>
    <nct_id>NCT04132466</nct_id>
  </id_info>
  <brief_title>ASSURE WCD Clinical Evaluation - Conversion Efficacy Study</brief_title>
  <acronym>ACE-CONVERT</acronym>
  <official_title>ASSURE WCD Clinical Evaluation - Conversion Efficacy Study (ACE-CONVERT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kestra Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regulatory and Clinical Research Institute Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kestra Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter single arm open label evaluation of the ASSURE Wearable Cardioverter
      Defibrillator (WCD) defibrillation waveform in adult cardiac patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate Ventricular Tachycardia/Ventricular Fibrillation
      (VT/VF) conversion efficacy in adult human subjects using the ASSURE Wearable Cardioverter
      Defibrillator (WCD) defibrillation waveform.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter single arm open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative first and second shock VT/VF conversion rate</measure>
    <time_frame>Through study procedure completion, average of 2 hours</time_frame>
    <description>The ratio of the number of subjects with successful (first or second shock) arrhythmia conversion using the Test System to the number of total inductions attempted with shocks delivered by the Test System. A successful arrhythmia conversion is defined as termination of an induced ventricular rhythm by first or second shock from the Test System to a non-shockable rhythm (rhythms other than VT or VF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First shock VT/VF conversion rate</measure>
    <time_frame>Through study procedure completion, average of 2 hours</time_frame>
    <description>The ratio of the number of subjects with successful (first shock) arrhythmia conversion using the Test System to the number of total inductions attempted with shocks delivered by the Test System. A successful arrhythmia conversion is defined as termination of an induced ventricular rhythm by first shock from the Test System to a non-shockable rhythm (rhythms other than VT or VF).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study procedure completion, average of 2 hours</time_frame>
    <description>Summary of adverse events that in the judgement of the investigator are at least possibly related to use of the investigational Test System.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Death, Sudden, Cardiac</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult cardiac patients who meet eligibility criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACE-CONVERT Study Test System</intervention_name>
    <description>defibrillation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, age â‰¥ 18 years

          2. Able and willing to provide written informed consent before undergoing any
             study-related procedures

          3. Scheduled for any of the following procedures:

               1. Electrophysiology study for induction of ventricular arrhythmias

               2. Non-invasive electrophysiology testing using an existing implantable
                  defibrillator

               3. Implantable cardioverter-defibrillator (ICD) replacement procedure during which
                  induction of a ventricular arrhythmia is planned

               4. Ablation of ventricular tachycardia (patients undergoing ventricular tachycardia
                  ablation in which only a substrate modification approach is planned, with no
                  intention of inducing a ventricular arrhythmia, should not be included)

        Exclusion Criteria:

          1. Any condition that by the judgement of the physician investigator precludes the
             subject's ability to comply with the study requirements

          2. Pregnancy

          3. Use of mechanical circulatory support (e.g. Left Ventricular Assist Device, Total
             Artificial Heart, intraaortic balloon pump or Impella)

          4. Documented nonchronic cardiac thrombus

          5. Atrial fibrillation or atrial flutter without therapeutic systemic anticoagulation

          6. Critical aortic stenosis

          7. Unstable coronary artery disease (CAD)

          8. Recent stroke or transient ischemic attack (TIA)

          9. Hemodynamic instability

         10. Currently implanted Boston Scientific S-ICD (due to location of implant relative to
             test system)

         11. Unstable angina

         12. New York Heart Association (NYHA) Class IV

         13. Left Ventricular Ejection Fraction (LVEF) &lt; 20%

         14. Any medical condition that by the judgement of the physician investigator, patient
             participation in this study is not in the best interest of the patient

         15. History of difficulty of ventricular arrhythmia induction

         16. Amiodarone use within 3 months before the study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marye Gleva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RON ROWBOTHAM, MSc</last_name>
    <phone>425-526-4913</phone>
    <email>ron.rowbotham@kestramedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Gustavson</last_name>
    <phone>425-526-4759</phone>
    <email>laura.gustavson@kestramedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Cardiovascular Research Foundation, Inc.</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda C Berg, RN</last_name>
      <phone>907-550-2283</phone>
      <email>lberg@alaskaheart.com</email>
    </contact>
    <contact_backup>
      <last_name>Deidre Rambur</last_name>
      <phone>907-264-5860</phone>
      <email>drambur@alaskaheart.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Willcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangeeta Lathkar-Pradhan, MBBS</last_name>
      <phone>734-232-5022</phone>
      <email>slathkar@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Wessel</last_name>
      <phone>7346152680</phone>
      <email>mbred@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice U Amsler, RN MSN</last_name>
      <phone>314-747-8542</phone>
      <email>jamslere@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jean Flanagan, RN MSN</last_name>
      <phone>314-4547451</phone>
      <email>jflanaga@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marye Gleva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Research and Innovation MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janey Barnhart, RN CNRN</last_name>
      <phone>253-403-7258</phone>
      <email>mbarnhart@multicare.org</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Edwards</last_name>
      <phone>253-403-7258</phone>
      <email>tdedwards@multicare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tariq Salam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

